Imaging Tumor Response to Therapy

1. Front Matter

   Pages i-xvii

   PDF

2. Methodological Bases

   1. Front Matter

      Pages 1-1

      PDF

   2. Surrogate Endpoints of Clinical Benefit

      • Giovannino Ciccone, Ileana Baldi

      Pages 3-14

   3. Response to Treatment: The Role of Imaging

      • Francesco Sardanelli, Anastasia Esseridou, Angelo S. Del Sole, Luca M. Sconfienza

      Pages 15-37

3. RECIST and Beyond: Assessing the Response to Treatment in Metastatic Disease

   1. Front Matter

      Pages 39-39

      PDF

   2. Gastrointestinal Stromal Tumors

      • Giovanni Grignani, Paola Boccone, Teresio Varetto, Stefano Cirillo

      Pages 41-60

   3. Renal Cancer

      • Cinzia Ortega, Camillo Porta, Manuela Racca, Filippo Russo

      Pages 61-75

   4. Liver Metastases in Colon Cancer

      • Lorenzo Capussotti, Luca Viganò, Francesco Leone, Delia Campanella

      Pages 77-91

4. RECIST and Beyond: Assessing the Response to Treatment in Locally Advanced Disease

   1. Front Matter

      Pages 93-93

      PDF

   2. Neoadjuvant Therapy in Breast Cancer

      • Laura Martincich, Ilaria Bertotto, Filippo Montemurro

      Pages 95-108

   3. Lung Cancer

      • Massimo Bellomi, Tommaso De Pas, Adele Tessitore, Lorenzo Preda

      Pages 109-125

   4. Pancreatic Cancer

      • Marcello Orsi, Claudio Losio, Michele Reni, Nadia Di Muzio, Francesco De Cobelli, Alessandro Del Maschio

      Pages 127-140

   5. Hepatocellular Carcinoma

      • Franco Brunello, Andrea Veltri

      Pages 141-157

Measurement of solid tumor response to treatment relies mainly on imaging. WHO tumor response criteria and, more recently, RECIST (response evaluation criteria in solid tumors) have provided means to objectively measure tumor response in clinical trials with imaging. These guidelines have been rapidly adopted in clinical practice to monitor patient treatment and for therapy planning. However, relying only on anatomical information is not always sufficient when evaluating new drugs that will reduce a tumor's functionality while preserving its size. Finding more reliable and reproducible measures of tumor response is one of the most important and difficult challenges facing modern radiology as it requires an entirely new approach to imaging. The aim of this book is to address the assessment of response to treatment by adopting a multidisciplinary perspective, just as occurs in real life in a comprehensive cancer center. Oncologists and imaging experts consider two cancer models, locally advanced disease and metastatic disease, jointly exploring both conventional and advanced means of measuring response to standard treatment protocols and new targeted therapies.

• Assessment of Response
• Functional Imaging
• Oncology
• Radiology

From the reviews:

“The book is well organized and is written in clear and succinct language. The figures and illustrations are of high quality and are up to date. … The book provides an excellent balance between the essential basic information and more advanced up to-date regimens. … an excellent book for all the medical professionals involved in oncology. The book is well priced and is an important addition to anyone who is interested in the oncology field.” (Khalid Khashoggi, Radiology, Vol. 270 (1), January, 2014)

“This relatively small book is organized into 3 parts with 9 chapters. … The book’s multidisciplinary perspective well addresses the assessment of therapeutic response. … The figures are clear and helpful, and the references are current. … I highly recommend this book to radiologists, nuclear physicians, oncologists, and imaging scientists.” (E. Edmund Kim, The Journal of Nuclear Medicine, Vol. 54 (6), June, 2013)

“A well-written, comprehensive review of the latest advances in oncologic therapy and how they have affected assessment of tumor response. … it discusses the latest therapies for different cancers in order to explain the need for new methods of assessing response to these new therapies. Although targeted at oncologists and imaging experts, the book also may be of interest to oncologic surgeons and radiation oncologists. … an excellent review of the strengths and weaknesses of the current size-based criteria used in many clinical trials.” (Vahid Yaghmai, Doody’s Book Reviews, February, 2013)

• Department of Medical Oncology, University of Turin Institute for Cancer Research and Treatment (IRCC), Candiolo (Turin), Italy

  Massimo Aglietta

• Radiology Unit, Institute for Cancer Research and Treatment (IRCC), Candiolo (Turin), Italy

  Daniele Regge

Policies and ethics